15 July 2020

We are excited to announce our continued support of Manus Neurodynamica as the company aims to revolutionise health care management through its Parkinson’s detecting technology. The funding from this round will be used to develop the Company's digital pen which provides an early warning of Parkinson's disease.


Manus Neurodynamica chief executive Dr Rutger Zietsma said: “We are excited to be working with Par Equity and our other new shareholders to accelerate the commercialisation of our neuromotor assessment technology. From our very first meeting it was obvious that we and Par Equity shared a vision of the global potential for the product, not just in Parkinson’s disease but in many other clinical indications.”

Par Equity partner Robert Higginson said:  “Par Equity first invested in Manus Neurodynamica in 2018 and we are delighted to continue supporting it as one of Scotland’s up and coming healthtech start-ups.

"The Company has developed a platform that dramatically improves the overall efficiency of the Parkinson’s disease diagnosis pathway in both primary and secondary care. The technology also has potential applications in adjacent fields in neurology.

"Manus is well placed to execute on this strategy and through our EIS Fund, our private investor network, the British Business Investments and the Scottish Investment Bank, we are able to draw on a breadth of firepower to support our portfolio.”

Read more here